Form 13-F position report

BIOMARIN PHARMACEUTICAL INC

Reported by North Star Investment Management Corp

BMRN 0.75 10/15/18 CUSIP 09061GAE1 Manager CIK 0001342857

Reported 0 shares, down 2,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q3 2018
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 7 Through Q3 2018

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value

Quarterly position history

How this manager's reported quarter-end position changed over time.

0 quarters
Quarterly reported position history for BIOMARIN PHARMACEUTICAL INC held by North Star Investment Management Corp.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
This position's reported history falls outside the five-year preview window. A free account unlocks it. Unlock full history

Who else reported the position

50 managers reported BIOMARIN PHARMACEUTICAL INC for Q3 2018.

Managers reporting BIOMARIN PHARMACEUTICAL INC in Q3 2018.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Bank of America Corporation Added 43,774,000 +16,411,000 < 0.01% $45,073,000 15 qtrs
Allianz Asset Management GmbH Unchanged 39,535,000 0 0.04% $40,970,000 14 qtrs
DEUTSCHE BANK AG Added 30,175,000 +175,000 0.02% $31,070,000 20 qtrs
Weiss Asset Management LP Unchanged 0 0 2.16% $28,040,000 1 qtr
SUSQUEHANNA INTERNATIONAL GROUP LLP Unchanged 0 0 < 0.01% $25,988,000 2 qtrs
AQR Arbitrage LLC New 24,825,000 +24,825,000 0.3% $25,686,000 1 qtr
WELLS FARGO & COMPANY MN Added 21,425,000 +19,142,000 < 0.01% $22,061,000 20 qtrs
CSS LLC IL Added 20,256,000 +17,756,000 0.89% $20,993,000 3 qtrs
CAPSTONE INVESTMENT ADVISORS LLC Added 17,000,000 +7,000,000 0.2% $17,589,000 2 qtrs
JPMorgan Chase & Co Added 15,702,000 +9,067,000 < 0.01% $16,273,000 20 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2018
Filed
October 11, 2018
Filing type
13F-HR
Position type
Convertible

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.